The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness. The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study to date.
Trial planning and execution to proceed as planned WASHINGTON , May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S.
Study to be conducted by North Carolina State University in 2024 Standard of care fails in 20 percent of cases and drug resistance is a problem Standard of care is expensive WASHINGTON , April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (or the “Company”),
WASHINGTON , March 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. , (NASDAQ: SXTP , SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the U.S.
Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals Tafenoquine ’s presumed mode of action against C. auris is differentiated from standard of care treatment Monash University will conduct the studies beginning in second quarter of 2024 WASHINGTON ,
To lead U.S. commercial relaunch of ARAKODA® (tafenoquine) for malaria prevention Will support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON , Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.
WASHINGTON , Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. ( NASDAQ: SXTP; SXTPW ) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its
WASHINGTON , Jan. 30, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. ( NASDAQ: SXTP; SXTPW ) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the pricing of its
Following a Type C meeting with FDA on January 17, 2024 , 60 Degrees Pharma (60P) now plans to conduct a pivotal clinical study in support of a future indication for tafenoquine for treatment of hospitalized babesiosis patients Patient enrollment to begin in summer of 2024 WASHINGTON , Jan.
WASHINGTON , Jan. 16, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it received written notice from the Nasdaq